On Monday, Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) was -15.15% drop from the session before settling in for the closing price of $0.06. A 52-week range for ADAP has been $0.04 – $0.86.
Annual sales at Healthcare sector company grew by 26.53% over the past five years. When this article was written, the company’s average yearly earnings per share was at -60.00%. With a float of $255.41 million, this company’s outstanding shares have now reached $265.05 million.
Adaptimmune Therapeutics Plc ADR (ADAP) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Adaptimmune Therapeutics Plc ADR stocks. The insider ownership of Adaptimmune Therapeutics Plc ADR is 3.64%, while institutional ownership is 27.49%. The most recent insider transaction that took place on Sep 02 ’25, was worth 950. In this transaction Chief Financial Officer of this company sold 96,000 shares at a rate of $0.01, taking the stock ownership to the 0 shares. Before that another transaction happened on Sep 02 ’25, when Company’s Chief Financial Officer proposed sale 16,000 for $0.06, making the entire transaction worth $942.
Adaptimmune Therapeutics Plc ADR (ADAP) Latest Financial update
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.01 earnings per share (EPS) during the time that was better than consensus figure (set at -0.18) by 0.17. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.06 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -60.00% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -11.87% during the next five years compared to 26.53% growth over the previous five years of trading.
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Trading Performance Indicators
You can see what Adaptimmune Therapeutics Plc ADR (ADAP) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.29. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.22.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.66, a number that is poised to hit -0.05 in the next quarter and is forecasted to reach -0.19 in one year’s time.
Technical Analysis of Adaptimmune Therapeutics Plc ADR (ADAP)
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) saw its 5-day average volume 150.27 million, a positive change from its year-to-date volume of 36.85 million. As of the previous 9 days, the stock’s Stochastic %D was 10.93%.
During the past 100 days, Adaptimmune Therapeutics Plc ADR’s (ADAP) raw stochastic average was set at 4.60%, which indicates a significant decrease from 5.66% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0351 in the past 14 days, which was higher than the 0.0209 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.1035, while its 200-day Moving Average is $0.2789. Nevertheless, the first resistance level for the watch stands at $0.0658 in the near term. At $0.0767, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.0833. If the price goes on to break the first support level at $0.0483, it is likely to go to the next support level at $0.0417. The third support level lies at $0.0308 if the price breaches the second support level.
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Key Stats
There are 265,052K outstanding shares of the company, which has a market capitalization of 14.55 million. As of now, sales total 178,030 K while income totals -70,810 K. Its latest quarter income was 13,680 K while its last quarter net income were -30,340 K.
